1Urata H, Bohem K D, Phlip A, et al . Cellular localization and regional distribution of an angiotensin Ⅱ forming chymase in the heart[J]. J Clin Invest, 1993,91(4):1269-1281.
2Azizi M, Chatellier G, Guyene T, et al . Additive effects of combined angiotensin converting enzyme inhibition and angiotensin Ⅱ antagonism on blood pressure and renin release in sodium-depleted normotensives [ J ]. Circulation, 1995,92 ( 4 ) :825-834.
3Russo D, Pisani A, Balletta M M, et al. Addictive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy[J].Am J Kid Dis,1999,33(5): 851-856.
2Mogensen CE. Management of early nephropathy in diabetic patients[J ]. Annu Rev Med 1995 ; (46) :79.
3Pistrosch F, Herbrig K Kindel B, et al. Rosiglitazone improves glomeular hyper filtration, renal endothelial dysfunction, and microalbuminutia of incipient diabetic nephropathy in patients[J]. Diabetes 2005; 54:2206 - 2211.
4Arima S, Kohagura K, Takeuchi K, et al. Biphasic vasodilator action of troglitazone on the renal microcirculation [J ]. J Am Soc Nephrol 2002 ; 13 : 342 - 349.
5Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of Losartan and Enalaprll on kidney function in hypertensive type 2 diabetics with early nephropathy[J]. Kidney Int 2000;58(2):762.
6Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J]. N Engl J Med 2001;345(12) :861.
